Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression.

Cancer Med · 2020 · PMC7333841 · PMID 32400122

Europe PMC DOI

hedged sentence

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

did not reach statistical significanceP = .084so close (0.05 < p ≤ 0.1)

The cumulative incidence of DM was also lower among men taking AP/AC but the difference did not reach statistical significance (3.4% vs 7.6% at 9.1 years, P = .084) (Figure S1B ). 10‐year CSS and OS in men taking AP/AC vs those who were not were 99% vs 95% ( P = .091) and 81% vs 81% ( P = .264), respectively. 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.